When does Eli Lilly's tirzepatide patent expire in the US?
The primary US patent for tirzepatide, marketed by Eli Lilly and Company, is expected to expire in November 2035. This patent covers the compound itself. [1]
What other exclusivity protections does tirzepatide have in the US?
In addition to compound patents, tirzepatide benefits from other forms of market exclusivity. These can include patents for methods of use, manufacturing processes, and formulations. [2] DrugPatentWatch.com tracks these various patent types, which can collectively extend the period of market protection beyond the initial compound patent expiration. [3]
How does patent expiration affect tirzepatide availability and cost?
Upon patent expiration, generic manufacturers may seek to market their own versions of tirzepatide. This typically leads to increased competition, which can result in lower prices for patients and wider accessibility to the medication. [4]
When might biosimilars for tirzepatide become available?
Tirzepatide is a small molecule drug, not a biologic. Therefore, biosimilar pathways, which are specific to biologic medications, do not apply. Instead, generic versions are expected to emerge after patent expiration. [5]
What are the current patent challenges for tirzepatide?
While the primary patent is set to expire in 2035, it is not uncommon for companies to face patent challenges from competitors seeking to enter the market earlier. Information on specific legal challenges or their outcomes would typically be found through patent litigation databases. [3]
Who are tirzepatide's main competitors?
Tirzepatide is used for type 2 diabetes and obesity. Competitors in these therapeutic areas include other GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. [6]
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/
[4] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs
[5] https://www.fda.gov/drugs/biosimilars/what-biosimilar-drug-product
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509205/